Zain Ebrahim
Stock Analyst at J.P. Morgan
(1.17)
# 9,401
Out of 12,268 analysts
27
Total ratings
42.9%
Success rate
-3.3%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPA: EAPI Euroapi S.A. | Maintained: Hold | $1.7 | $1.48 | +15.18% | 1 | May 13, 2026 | |
| LON: GSK GSK plc | Maintained: Sell | $17 | $1,915.00 | -99.11% | 17 | Apr 29, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Buy | $2,400 → $2,000 | $1,459.00 | +37.08% | 2 | Mar 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Hold | $1,650 → $2,050 | $1,723.63 | +18.94% | 2 | Dec 8, 2025 | |
| LON: OXB Oxford Biomedica plc | Maintained: Hold | $550 | $618.00 | -11.00% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | $675 | $492.80 | +36.97% | 1 | Jul 28, 2025 | |
| SWX: BANB Bachem Holding AG | Maintained: Buy | $74 → $85 | $78.50 | +8.28% | 3 | Jul 25, 2025 |
Euroapi S.A.
May 13, 2026
Maintained: Hold
Price Target: $1.7
Current: $1.48
Upside: +15.18%
GSK plc
Apr 29, 2026
Maintained: Sell
Price Target: $17
Current: $1,915.00
Upside: -99.11%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Maintained: Buy
Price Target: $2,400 → $2,000
Current: $1,459.00
Upside: +37.08%
Genmab A/S
Dec 8, 2025
Maintained: Hold
Price Target: $1,650 → $2,050
Current: $1,723.63
Upside: +18.94%
Oxford Biomedica plc
Dec 8, 2025
Maintained: Hold
Price Target: $550
Current: $618.00
Upside: -11.00%
Lonza Group AG
Jul 28, 2025
Maintained: Buy
Price Target: $675
Current: $492.80
Upside: +36.97%
Bachem Holding AG
Jul 25, 2025
Maintained: Buy
Price Target: $74 → $85
Current: $78.50
Upside: +8.28%